Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aytu BioPharmaAYTU -3.91%42 3-Year EBITDA Growth Rate is 65.20% as of Mar. 2026, which is 6% below its 10-year median of 69.45. GuruFocus rates AYTU with a GF Score™ of 42/100 and a GF Value™ of $0.89 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 807 Drug Manufacturers companies, Aytu BioPharma ranks better than 92.32% on this metric.
During the past 12 months, Aytu BioPharma's average EBITDA Per Share Growth Rate was -299.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 65.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Aytu BioPharma was 81.00% per year. The lowest was 63.50% per year. And the median was 69.45% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Aytu BioPharma 3-Year EBITDA Growth Rate Related Terms
AYTU vs BFRI, TXMD, ETST: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aytu BioPharma 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Aytu BioPharma's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 65.20% mean?
Aytu BioPharma (AYTU) has a 3-Year EBITDA Growth Rate of 65.20% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Aytu BioPharma and its competitors. This is near median its historical median of 69.45. Over the past decade, Aytu BioPharma's 3-Year EBITDA Growth Rate has ranged from 63.50 to 81.00. According to the industry distribution chart, Aytu BioPharma ranks #62 out of 807 companies in the Drug Manufacturers industry, placing it in the top 7.7%.
Is Aytu BioPharma's 3-Year EBITDA Growth Rate too high?
Aytu BioPharma's current 3-Year EBITDA Growth Rate of 65.20% is near median its 10-year median of 69.45. Over the past 10 years, this metric has ranged from a low of 63.50 to a high of 81.00. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Aytu BioPharma's value of 65.20% is 632.6% above this industry median. Based on the distribution chart, Aytu BioPharma ranks #62 out of 807 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Aytu BioPharma has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aytu BioPharma's 3-Year EBITDA Growth Rate compare to BFRI and TXMD?
According to the Drug Manufacturers industry distribution chart, Aytu BioPharma ranks #62 out of 807 companies for 3-Year EBITDA Growth Rate. This places Aytu BioPharma in the top 8% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Aytu BioPharma's value of 65.20% is 632.6% above this benchmark. Historically, Aytu BioPharma's own 3-Year EBITDA Growth Rate has ranged from 63.50 to 81.00 over the past decade. While the company's 10-year median is 69.45 vs. the industry median of 8.90, Aytu BioPharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 807 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aytu BioPharma's current 3-Year EBITDA Growth Rate of 65.20% is 632.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Aytu BioPharma and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aytu BioPharma's current 3-Year EBITDA Growth Rate is 65.20%, which is near median its own 10-year median of 69.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aytu BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Aytu BioPharma (AYTU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.89, compared to a current price of $2.19 — trading 145.5% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 65.20%, which is near median its 10-year median of 69.45 and 632.6% above the Drug Manufacturers industry median of 8.90. Aytu BioPharma's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Aytu BioPharma (AYTU), the current 3-Year EBITDA Growth Rate is 65.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aytu BioPharma (AYTU) Overvalued in 2026?
Based on GuruFocus' analysis, Aytu BioPharma stock appears to be overvalued.
The current stock price of $2.19 is trading 145.5% above its estimated GF Value™ of $0.89.
GuruFocus considers Aytu BioPharma to be Significantly Overvalued.
Key valuation signals for AYTU:
3-Year EBITDA Growth Rate: 65.20% (near median its 10-year median of 69.45)
GF Value™: $0.89 vs. price of $2.19 (145.5% above fair value)
Industry Position: 632.6% above the Drug Manufacturers median (#62 of 807)
No single metric tells the full story. See the AYTU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
42GF Score
Get the complete analysis for AYTU
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AYTU has been successfully added to your 
